News | January 23, 2024
Granules India posts Q3 FY24 consolidated PAT at Rs. 125.65 Cr
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
The bold, dynamic, and new logo unveiled in this process captures the essence of the 'Better Together' theme
The PAI was conducted for two drug product applications (ANDAs) filed from this facility
Automated parallel capillary electrophoresis system simplifies protein analysis
Collaboration streamlines patient access to oncology clinical trials
Subscribe To Our Newsletter & Stay Updated
